Pharmacotherapy for Parkinson's Disease
Identifieur interne : 000F89 ( Main/Exploration ); précédent : 000F88; suivant : 000F90Pharmacotherapy for Parkinson's Disease
Auteurs : Chen [États-Unis] ; Swope [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2007-12.
English descriptors
- KwdEn :
Abstract
The available pharmacotherapies for Parkinson's disease address symptomatology because no agent has been demonstrated to provide definite neuroprotection against the disease. Choice of pharmacotherapy must include consideration of short‐term benefits as well as long‐term consequences. Patients with mild Parkinson's disease often function adequately without symptomatic treatment. However, recent data suggest that initiation of treatment with a well‐tolerated agent (e.g., the monoamine oxidase [MAO]‐B inhibitor rasagiline) in the absence of functional impairment is associated with improved long‐term outcomes. Consideration should also be given to many patient‐specific factors, including patient expectations, level of disability, employment status, functional as well as chronologic age, expected efficacy and tolerability of drugs, and response to previous Parkinson's disease therapies. Increasingly, initial monotherapy begins with a nondopaminergic agent or, if the patient is considered functionally young, a dopamine agonist. Since Parkinson's disease is a progressive disorder, adjustments to pharmacotherapy must be expected over time. When greater symptomatic relief is desired, or in the more frail elderly patient, levodopa therapy should be considered. If motor fluctuations develop, addition of a catechol‐O‐methyltransferase inhibitor or MAO‐B inhibitor should be considered. For management of levodopa‐induced dyskinesias, addition of amantadine is an option. Surgery may be considered when patients need additional symptomatic control or are experiencing severe motor complications despite pharmacologically optimized therapy.
Url:
DOI: 10.1592/phco.27.12part2.161S
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacotherapy for Parkinson's Disease</title><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5A800F7EEF013C71684DCAC048CE012540514B73</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1592/phco.27.12part2.161S</idno><idno type="url">https://api.istex.fr/document/5A800F7EEF013C71684DCAC048CE012540514B73/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000025</idno><idno type="wicri:Area/Main/Curation">000022</idno><idno type="wicri:Area/Main/Exploration">000F89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacotherapy for Parkinson's Disease</title><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Neurology, School of Medicine, Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-12">2007-12</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">12P2</biblScope><biblScope unit="page" from="161S">161S</biblScope><biblScope unit="page" to="173S">173S</biblScope></imprint><idno type="ISSN">0277-0008</idno></series><idno type="istex">5A800F7EEF013C71684DCAC048CE012540514B73</idno><idno type="DOI">10.1592/phco.27.12part2.161S</idno><idno type="ArticleID">PHAR297</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COMT inhibitors</term><term>MAO‐B inhibitors</term><term>Parkinson's disease</term><term>amantadine</term><term>anticholinergics</term><term>catechol‐O‐methyltransferase</term><term>dopamine</term><term>levodopa</term><term>monoamine oxidase</term><term>pharmacotherapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The available pharmacotherapies for Parkinson's disease address symptomatology because no agent has been demonstrated to provide definite neuroprotection against the disease. Choice of pharmacotherapy must include consideration of short‐term benefits as well as long‐term consequences. Patients with mild Parkinson's disease often function adequately without symptomatic treatment. However, recent data suggest that initiation of treatment with a well‐tolerated agent (e.g., the monoamine oxidase [MAO]‐B inhibitor rasagiline) in the absence of functional impairment is associated with improved long‐term outcomes. Consideration should also be given to many patient‐specific factors, including patient expectations, level of disability, employment status, functional as well as chronologic age, expected efficacy and tolerability of drugs, and response to previous Parkinson's disease therapies. Increasingly, initial monotherapy begins with a nondopaminergic agent or, if the patient is considered functionally young, a dopamine agonist. Since Parkinson's disease is a progressive disorder, adjustments to pharmacotherapy must be expected over time. When greater symptomatic relief is desired, or in the more frail elderly patient, levodopa therapy should be considered. If motor fluctuations develop, addition of a catechol‐O‐methyltransferase inhibitor or MAO‐B inhibitor should be considered. For management of levodopa‐induced dyskinesias, addition of amantadine is an option. Surgery may be considered when patients need additional symptomatic control or are experiencing severe motor complications despite pharmacologically optimized therapy.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></region><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5A800F7EEF013C71684DCAC048CE012540514B73
|texte= Pharmacotherapy for Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |